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Abstract
Blood transfusions are indicated for some acute complications of sickle cell disease (SCD). To
characterize the SCD population at increased risk of transfusion-associated complications, Georgia hospital discharge data were used to estimate the frequency of intermittent transfusions and
the proportion of patients receiving them at multiple institutions. Ten years of data (2007-2016)
showed almost 19% of patients with SCD (1585/8529) received transfusions at more than one

Funding information
This publication was supported by cooperative
agreement number NU58 DD001138, funded
by the Centers for Disease Control and Prevention. The Sickle Cell Data Collection Program
in Georgia is made possible by support from
the CDC Foundation (Sanofi Inc., Global Blood
Therapeutics, Pfizer and Doris Duke Charitable
Foundation; grant number CDC-RFA-OT181802).

1

hospital. The likelihood of multisite transfusions increased from ages 18 through 40 and with the
number of transfusions received. The results support the need to track and share transfusion histories in order to reduce complication risks.
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INTRODUCTION

reactions (DHTRs). The risk of DHTRs is more common in intermittently transfused versus chronically transfused patients, and increases

Many individuals with sickle cell disease (SCD) will develop acute

when patients receive multiple transfusions.2–5 This could be related

complications that require urgent transfusions, such as acute stroke,

to having incomplete transfusion histories available to transfusing

acute chest syndrome, splenic or hepatic sequestration, aplastic cri-

providers. Past studies show that a significant percentage of individ-

sis, or multisystem organ failure. Chronic transfusions are used for

uals with serologically undetectable antibody titer due to evanescence

primary and secondary stroke prophylaxis, prevention of recurrent

are transfused at multiple health centers and at risk for DHTRs, hyper-

splenic sequestration, and frequent pain

episodes.1

Chronic transfu-

hemolysis, and further alloimmunization.2,6

sions are typically administered in an outpatient setting at a single

Georgia is home to one of the largest SCD populations in the United

center. Urgent transfusions may occur at multiple different sites over

States—an estimated 7000-8500 of the 90 000-120 000 individuals

time.2

in the country with SCD.7,8 To characterize the SCD population at

Even with appropriate pretransfusion testing and iron chelation,

increased risk of transfusion-associated complications, the Registry

red blood cell (RBC) transfusions still carry risks of complications, such

and Education for Hemovigilance in Hemoglobinopathy Transfusion

as alloimmunization and iron overload. RBC alloimmunization is par-

Therapy (REdHHoTT) project in Georgia used hospital discharge data

ticularly problematic in SCD because it limits subsequent transfusion

to estimate the frequency of intermittent transfusions and the propor-

options and can cause potentially fatal delayed hemolytic transfusion

tion of patients receiving them at multiple institutions.

Abbreviations: DHTR, delayed hemolytic transfusion reaction; ED, emergency department; REdHHoTT, Registry and Education for Hemovigilance in Hemoglobinopathy Transfusion Therapy;
SCD, sickle cell disease.
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F I G U R E 1 Patients with sickle cell disease (n =
8529) identified in hospital discharge data in
Georgia, 2007-2016, by the number of intermittent
transfusions and hospitals where >1 intermittent
transfusions were received

F I G U R E 2 Multiply transfused patients with sickle cell disease (n = 3073) with single-site versus multisite intermittent transfusions, by
number of cumulative transfusions, 2007-2016
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RESULTS

years received them at different hospitals, a vast majority of patients
(529/671, or 80%) who had 10 or more transfusions received them at

Using longitudinal data from Georgia’s Sickle Cell Data Collection

multiple sites. There was no significant difference in sex distribution

Program, we characterized the use of intermittent transfusions for

between patients who were multiply transfused at a single site (53%

treatment of SCD in emergency departments (EDs) and inpatient set-

female, 46.7% male) versus those who received multisite transfusions

tings in Georgia from 2007 to 2016. Patients receiving outpatient

(56.6% female, 43.4% male).

transfusions are not captured in this dataset as this analysis used hos-

Out of the 1585 patients who had multisite transfusions, 175

pital discharge data (ED and inpatient data only). A transfusion was

patients (11%) were <10 years of age, 207 (13.1%) were 11-17, 471

defined as a single transfusion episode, regardless of the blood vol-

(29.7%) were 18-25, 488 (30.8%) were 26-40, and 244 (15.4%) were

ume given. Individuals with SCD were defined as those who had three

>40.

or more encounters with an SCD diagnosis code during the study
period.9,10 Patient age was defined as of the date the first transfusion

3

DISCUSSION

was received during the study period. Based on a previous, unpublished
analysis of Georgia Medicaid claims data, inpatient and ED transfu-

These findings show that almost one-fifth of patients within Geor-

sions represent about one-third of all SCD-related transfusions in the

gia receive intermittent transfusions at multiple hospital sites. Given

state.

the lack of a statewide system to share patient transfusion histo-

A total of 8529 unique patients with SCD were identified in Geor-

ries across hospitals, this likely leads to increased risks of transfusion

gia. Of these, 4584 (53.7%) had at least one ED or inpatient transfu-

complications such as RBC alloimmunization and DHTRs. Prior case

sion, and more than two-thirds of these patients (n = 3073) received

reports from Georgia have demonstrated the potentially fatal conse-

multiple transfusions (Figure 1).

quences of patients receiving transfusions without their alloantibody

Fewer than half of patients with SCD who had multiple transfu-

history being known.6 Additionally, most hospitals providing intermit-

sions received them all at the same hospital (1488/3073); nearly one in

tent transfusions to patients with SCD do so infrequently. Though a few

five (589/3073) received transfusions at three or more sites (Figure 1).

Georgia hospitals are high-volume intermittent transfusion providers

The likelihood of multisite transfusions increased with the total num-

for patients with SCD, many others average fewer than one SCD trans-

ber of transfusions received (Figure 2); the Cochran-Armitage trend

fusion per year. With limited experience, provider knowledge and prac-

test was significant, at P < .0001. While roughly one-third of the 798

tice may not be current with the latest evidence-based recommenda-

patients who had exactly two intermittent transfusions over the 10

tions for transfusion in SCD.
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While 30% of patients who received multisite transfusions were

Global Blood Therapeutics, Pfizer and Doris Duke Charitable Foun-

between 18 and 25 and presumably transitioning from pediatric to

dation; grant number CDC-RFA-OT18-1802), under the direction of

adult facilities, the rate was similar in those who were 26-40, sug-

the Division of Blood Disorders, Centers for Disease Control and

gesting age-related transition from pediatric to adult care was impor-

Prevention (CDC). The contents of this publication are solely the

tant but not solely responsible for these findings. These results also

responsibility of the authors and do not necessarily represent the

highlight the need to address alloantibody history during transition

official views of the CDC or the Department of Health and Human

planning.

Services.

Additionally, there was no significant difference in sex distribution between patients who were multiply transfused at a single institution versus those receiving multisite transfusions, suggesting that
pregnancy did not increase the risk of receiving multisite transfusions.
Some Georgia residents may also be intermittently receiving transfu-
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the extent of multisite transfusions.
We are unable to accurately determine the impact of transfusions
at multiple centers on alloimmunization rates and frequency of DHTRs
due to retrospective use of administrative datasets. Future prospective
studies should be considered to accurately characterize this risk.
The National Heart, Lung, and Blood Institute’s 2014 expert panel
report, Evidence-Based Management of Sickle Cell Disease, recommends
that patients with sickle cell receive blood with extended phenotypic
matching, including matching for C, E, and Kell antigens.11 The guidance further advises that providers obtain an accurate transfusion history. British guidelines from 2017 state “a transfusion history should be
obtained in all patients with SCD requiring transfusion, whether elective or emergency. Close communication is essential between clinical
and laboratory teams so that appropriate blood is given.”12 Failure to
follow these recommendations can result in formation of new alloantibodies or reactivation of a previous one—even ones that may no longer
be serologically detectable—resulting in a potentially lethal DHTR.2–4
Previous studies show that a centralized regional or statewide
transfusion database can enhance transfusion safety, but privacy
issues have limited the establishment of a national database.2,3 The
REdHHoTT project is assessing the feasibility of implementing a transfusion data registry using software applications designed to interface
with hospital blood bank data systems, retrieve select patient data,
and store them in a provider-accessible database. Antibody cards are
known to prevent potential DHTRs, but they are not standard practice at all hospitals.13 REdHHoTT is also developing a campaign to
inform patients about the need to carry transfusion history information. This is being proposed using personalized approaches such as
physical cards, smartphone health data apps, or photographs of blood
bags and medical charts, and other technologies. Prospective studies
that include the cost and benefit analysis of preventive approaches are
required to determine the impact on DHTR and alloimmunization.
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